Pharmacokinetic analysis identifies a factor VIII immunogenicity threshold after AAV gene therapy in hemophilia A mice

Advances in the development of novel treatment options for hemophilia A are prevalent. However, the anti–factor VIII (FVIII) neutralizing antibody (inhibitor) response to existing FVIII products remains a major treatment challenge. Although some novel products are designed to function in the presenc...

Descripción completa

Detalles Bibliográficos
Autores principales: Lundgren, Taran S., Denning, Gabriela, Stowell, Sean R., Spencer, H. Trent, Doering, Christopher B.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Society of Hematology 2022
Materias:
Gene Therapy
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9043920/
https://www.ncbi.nlm.nih.gov/pubmed/35286375
http://dx.doi.org/10.1182/bloodadvances.2021006359

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9043920/
https://www.ncbi.nlm.nih.gov/pubmed/35286375
http://dx.doi.org/10.1182/bloodadvances.2021006359

Ejemplares similares